Luteolin and fisetin suppress oxidative stress by modulating sirtuins and forkhead box O3a expression under in vitro diabetic conditions.
10.4162/nrp.2017.11.5.430
- Author:
Arang KIM
1
;
Wooje LEE
;
Jung Mi YUN
Author Information
1. Department of Food and Nutrition, Chonnam National University, Yongbong-ro, Buk-gu, Gwangju 61186, Korea. sosung75@jnu.ac.kr
- Publication Type:Brief Communication
- Keywords:
Diabetes mellitus;
oxidative stress;
monocytes
- MeSH:
Blotting, Western;
Diabetes Complications;
Diabetes Mellitus;
Glucose;
Humans;
Hyperglycemia;
In Vitro Techniques*;
Luteolin*;
Monocytes;
NADP;
Oxidative Stress*;
Oxidoreductases;
Reactive Oxygen Species;
Sirtuins*;
Superoxides
- From:Nutrition Research and Practice
2017;11(5):430-434
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/OBJECTIVE: Chronic hyperglycemia induces oxidative stress via accumulation of reactive oxygen species (ROS) and contributes to diabetic complications. Hyperglycemia induces mitochondrial superoxide anion production through the increased activity of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. This study aimed to determine whether fisetin and luteolin treatments suppress the oxidative stress by modulating the expression of sirtuins (SIRTs) and forkhead box O3a (FOXO3a) under hyperglycemic conditions in human monocytes. MATERIALS/METHODS: Human monocytic cells (THP-1) were cultured under osmotic control (14.5 mmol/L mannitol), normoglycemic (NG, 5.5 mmol/L glucose), or hyperglycemic (HG, 20 mmol/L glucose) conditions, in the absence or presence of fisetin and luteolin for 48 h. To determine the effect of fisetin and luteolin treatments on high glucose-induced oxidative stress, western blotting and intracellular staining were performed. RESULTS: Hyperglycemic conditions increased the ROS production, as compared to normoglycemic condition. However, fisetin and luteolin treatments inhibited ROS production under hyperglycemia. To obtain further insight into ROS production in hyperglycemic conditions, evaluation of p47phox expression revealed that fisetin and luteolin treatments inhibited p47phox expression under hyperglycemic conditions. Conversely, the expression levels of SIRT1, SIRT3, SIRT6, and FOXO3a were decreased under high glucose conditions compared to normal glucose conditions, but exposure to fisetin and luteolin induced the expression of SIRT1, SIRT3, SIRT6, and FOXO3a. The above findings suggest that fisetin and luteolin inhibited high glucose-induced ROS production in monocytes through the activation of SIRTs and FOXO3a. CONCLUSIONS: The results of our study supports current researches that state fisetin and luteolin as potential agents for the development of novel strategies for diabetes.
